BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer 2019;7:307. [PMID: 31730025 DOI: 10.1186/s40425-019-0796-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Schroeder SM, Nelde A, Walz JS. Viral T-cell epitopes – Identification, characterization and clinical application. Seminars in Immunology 2023;66:101725. [DOI: 10.1016/j.smim.2023.101725] [Reference Citation Analysis]
2 Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, Terreux R, Lucifora J, Durantel D, Verrier B. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus. Antiviral Res 2023;209:105483. [PMID: 36496142 DOI: 10.1016/j.antiviral.2022.105483] [Reference Citation Analysis]
3 Wang J, Weiss T, Neidert MC, Toussaint NC, Naghavian R, Sellés Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin JH, McKay R, Wu CJ, Lutterotti A, Sospedra M, Moch H, Greiner EF, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clin Cancer Res 2022;28:5368-82. [PMID: 36228153 DOI: 10.1158/1078-0432.CCR-22-1741] [Reference Citation Analysis]
4 Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 2022;13:6401. [PMID: 36302754 DOI: 10.1038/s41467-022-33746-3] [Reference Citation Analysis]
5 Zhang E, Ma Z, Lu M. Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases. Cell Mol Life Sci 2022;79:547. [PMID: 36224474 DOI: 10.1007/s00018-022-04582-x] [Reference Citation Analysis]
6 Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, Wu CJ, Pentelute BL, Irvine DJ. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A 2022;119:e2204078119. [PMID: 35914154 DOI: 10.1073/pnas.2204078119] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Duan S, Liu S. Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. Front Immunol 2022;13:842746. [PMID: 35371060 DOI: 10.3389/fimmu.2022.842746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mao L, Liu C, Liu JY, Jin ZL, Jin Z, Xue RY, Feng R, Li GC, Deng Y, Cheng H, Zou QM, Li HB. Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response. Front Immunol 2022;13:833418. [PMID: 35356002 DOI: 10.3389/fimmu.2022.833418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yang J, Tseng J, Yu G, Luo Y, Huang CF, Hong Y, Chuang T. Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics 2022;14:423. [DOI: 10.3390/pharmaceutics14020423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Rüthrich MM, Giesen N, Mellinghoff SC, Rieger CT, von Lilienfeld-toal M. Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences. Vaccines 2022;10:182. [DOI: 10.3390/vaccines10020182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Merk H, Amran-gealia T, Finkelmeier D, Kohl C, Pichota I, Stern N, Rupp S, Goldblum A, Burger-kentischer A. Human-Based Immune Responsive In Vitro Infection Models for Validation of Novel TLR4 Antagonists Identified by Computational Discovery. Microorganisms 2022;10:243. [DOI: 10.3390/microorganisms10020243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rammensee H. Identification of tumor antigens for T-cell-mediated cancer immunotherapy. Cancer Vaccines as Immunotherapy of Cancer 2022. [DOI: 10.1016/b978-0-12-823901-8.00010-8] [Reference Citation Analysis]
13 Roerden M, Walz JS. Tumorimpfstoffe. Onkologe 2021;27:1101-1108. [DOI: 10.1007/s00761-021-01012-8] [Reference Citation Analysis]
14 Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front Immunol 2021;12:701501. [PMID: 34322129 DOI: 10.3389/fimmu.2021.701501] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 30.5] [Reference Citation Analysis]
15 Nelde A, Maringer Y, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HG, Walz JS. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Front Immunol 2021;12:705974. [PMID: 34305947 DOI: 10.3389/fimmu.2021.705974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rammensee HG, Gouttefangeas C, Heidu S, Klein R, Preuß B, Walz JS, Nelde A, Haen SP, Reth M, Yang J, Tabatabai G, Bösmüller H, Hoffmann H, Schindler M, Planz O, Wiesmüller KH, Löffler MW. Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. Vaccines (Basel) 2021;9:428. [PMID: 33923363 DOI: 10.3390/vaccines9050428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
17 Nelde A, Rammensee HG, Walz JS. The Peptide Vaccine of the Future. Mol Cell Proteomics 2021;20:100022. [PMID: 33583769 DOI: 10.1074/mcp.R120.002309] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
18 Richardson JR, Schöllhorn A, Gouttefangeas C, Schuhmacher J. CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. Cancers (Basel) 2021;13:596. [PMID: 33546283 DOI: 10.3390/cancers13040596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
19 Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med 2021;25:639-51. [PMID: 33336901 DOI: 10.1111/jcmm.16214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
20 Hossam N, Matboli M, Shehata HH, Aboelhussein MM, Hassan MK, Eissa S. Toll-like receptor immune modulatory role in personalized management of colorectal cancer, review of literature. Expert Review of Precision Medicine and Drug Development 2020;5:455-68. [DOI: 10.1080/23808993.2020.1816136] [Reference Citation Analysis]
21 Rammensee HG, Löffler MW. [Individualized immunotherapy for malignant tumors using peptide vaccines-maybe it does work after all?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1380-7. [PMID: 33034694 DOI: 10.1007/s00103-020-03227-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Nguyen MT, Matsuo M, Niemann S, Herrmann M, Götz F. Lipoproteins in Gram-Positive Bacteria: Abundance, Function, Fitness. Front Microbiol 2020;11:582582. [PMID: 33042100 DOI: 10.3389/fmicb.2020.582582] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
23 Haen SP, Löffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol 2020;17:595-610. [PMID: 32572208 DOI: 10.1038/s41571-020-0387-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 23.7] [Reference Citation Analysis]
24 Rammensee HG, Löffler MW, Walz JS, Bokemeyer C, Haen SP, Gouttefangeas C. [Tumor vaccines-therapeutic vaccination against cancer]. Internist (Berl) 2020;61:690-8. [PMID: 32462251 DOI: 10.1007/s00108-020-00814-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Ghosh M, Gauger M, Denk M, Rammensee H, Stevanović S. Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture.. [DOI: 10.1101/2020.01.22.916189] [Reference Citation Analysis]